Xeris Biopharma Holdings, Inc. (FRA:2B30)

Xeris Biopharma Holdings Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 26, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	993	488	294	169	321	-
Market Cap Growth	124.44%	66.23%	73.53%	-47.33%	-	-
Enterprise Value	1,136	683	440	211	317	-
Last Close Price	6.20	3.23	2.10	1.15	2.20	-
PS Ratio	4.38	2.49	1.98	1.64	7.37	-
PB Ratio	-1353.70	-17.07	-47.86	4.00	3.84	-
EV/Sales Ratio	4.96	3.48	2.97	2.05	7.26	-
Debt / Equity Ratio	-299.25	-9.17	-33.79	4.38	0.93	2.58
Asset Turnover	0.77	0.63	0.49	0.34	0.21	0.15
Inventory Turnover	0.73	0.85	0.90	1.06	1.01	1.77
Quick Ratio	1.25	1.12	1.17	2.08	1.52	4.99
Current Ratio	1.93	1.67	1.64	2.54	1.80	5.40
Return on Equity (ROE)	-	-	-324.20%	-134.83%	-190.28%	-378.20%
Return on Assets (ROA)	2.88%	-5.33%	-8.25%	-15.78%	-28.45%	-38.02%
Return on Capital (ROIC)	3.98%	-7.42%	-11.81%	-24.01%	-43.37%	-52.67%
Return on Capital Employed (ROCE)	6.30%	-12.40%	-19.40%	-30.20%	-46.80%	-62.30%
Earnings Yield	-1.34%	-10.85%	-19.18%	-52.34%	-33.59%	-
FCF Yield	0.86%	-7.49%	-15.18%	-57.18%	-26.44%	-
Buyback Yield / Dilution	-8.48%	-6.61%	-1.51%	-71.62%	-85.32%	-63.32%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.